Clinical Trials

Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of darovasertib in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (mUM) who will be randomized to receive either darovasertib + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Phase 2 multi-center open-label darovasertib study in patients with primary uveal melanoma (UM) requiring either enucleation or plaque brachytherapy.

Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma

Trial in collaboration with Servier to initiate in H2 '26

Phase 1/2, multicenter, study evaluating the safety, efficacy, and pharmacokinetics of IDE849 in patients with DLL3-expressing tumors including small cell lung cancer.

Part 1A Dose Escalation will evaluate IDE849 monotherapy.

Phase 1/2, multicenter, study evaluating the safety, efficacy, and pharmacokinetics of IDE849 in patients with DLL3-expressing tumors including small cell lung cancer.

Part 1B Dose Escalation will evaluate IDE849 in combination with durvalumab or IDE161.

Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy.

Multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Open label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of  IDE574  as monotherapy in locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in locally advanced or metastatic ER+, HER2- breast cancer.